Given we don't have a whole lot of shorters that need to cover in Race, only one thing is going to improve the SP and that is a clear and realistic development plan along with management who can deliver on the plan. Investors are rightly skeptical about Race given the recent drama, but none of this drama has changed the fundamental potential of bisantrene. The things that need fixing can be fixed.
Race wasn't worth 4.5c when I first started buying the stock. The fun of investing in biotechs is the market rarely gets their valuation correct.
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-165
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
